Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatoid Arthritis

RA Treatment Options Expanded with New Infusible TNF Inhibitor

Richard Quinn  |  August 21, 2013

FDA approves second infusible anti–tumor necrosis factor treatment for patients with moderate to severe rheumatoid arthritis. (posted Aug. 16, 2013)

ACR 2013 State-of-the-Art Clinical Symposium: What’s Next in Therapy for Osteoarthritis, Rheumatoid Arthritis, and Lupus?

Kathy Holliman  |  August 1, 2013

Experts highlight treatment advances and challenges ahead in OA, RA, and systemic lupus erythematosus (SLE)

B-Cell Genes Interact to Increase Risk for Rheumatoid Arthritis

Lara C. Pullen, PhD  |  July 31, 2013

Researchers demonstrate that BANK1 is a susceptibility gene for RA, and it may play a role in RA pathogenesis. (posted June 31, 2013)

California Rheumatology Alliance 2013 Meeting: Aim for Remission in Rheumatoid Arthritis

Stephanie Cajigal  |  July 1, 2013

Early diagnosis and aggressive treatment of RA is key, expert says

California Rheumatology Alliance 2013 Meeting: The Future of Rheumatoid Arthritis

Stephanie Cajigal  |  July 1, 2013

Treatment for RA should involve targeting subclinical disease and reversing immune dysregulation, expert says

Tofacitinib and Other Kinase Inhibitors Offer New Approach to Treating Rheumatoid Arthritis

Deborah L. Parks, MD  |  June 1, 2013

Small molecule kinase inhibitors, such as JAK inhibitors, provide a novel route for rheumatic disease treatment—and may promote our understanding of the immune system’s complexities

Will New Rheumatoid Arthritis Blood Test Improve Early Diagnosis?

Richard Quinn  |  May 6, 2013

Two new blood tests may boost the accuracy of RA diagnose, although more data needed. (posted May 5, 2013)

DNA Methylation Modifies Genetic Risk for Rheumatoid Arthritis

Lara C. Pullen, PhD  |  April 12, 2013

A first-of-its-kind study has been published that integrates genotype and epigenotype data across the entire genome.

Prednisone Might be the Missing Ingredient in the American College of Rheumatology’s Recommendations for Treating Patients with Rheumatoid Arthritis

John Kirwan, MD  |  April 1, 2013

A combination therapy with glucocorticoids may be the gold standard for treating patients with rheumatoid arthritis (RA)

Is Predisone 3 mg/day an Appropriate Dose for Patients with Rheumatoid Arthritis?

Theodore Pincus, MD  |  April 1, 2013

 Long-term, low-dose prednisone at less than 5 mg/day appears tolerable and effective for many patients with rheumatoid arthritis (RA)

  • « Previous Page
  • 1
  • …
  • 57
  • 58
  • 59
  • 60
  • 61
  • …
  • 75
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences